SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Historical Holders from Q1 2014 to Q3 2025

Symbol
SUPN on Nasdaq
CUSIP
868459108
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
56M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
57.7M
Holdings value
$2.76B
% of all portfolios
0.005%
Grand Portfolio weight change
0%
Number of holders
305
Number of buys
146
Number of sells
-160
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14.7% $266M 8.2M BlackRock, Inc. Mar 31, 2025
ARMISTICE CAPITAL, LLC 5.06% -46.9% $136M -$113M 2.84M -45.4% Armistice Capital, LLC Sep 30, 2025

Institutional Holders of SUPERNUS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (SUPN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 57.7M $2.76B -$55.6M $47.79 305
2025 Q2 59.5M $1.87B +$9.63M $31.52 291
2025 Q1 59.1M $1.94B -$15.5M $32.75 288
2024 Q4 59.5M $2.15B -$16.2M $36.16 289
2024 Q3 59.7M $1.86B +$51.6M $31.18 268
2024 Q2 58.4M $1.56B +$37.8M $26.75 241
2024 Q1 56.5M $1.93B -$19.6M $34.11 246
2023 Q4 57.1M $1.65B +$26.4M $28.94 243
2023 Q3 56.7M $1.56B -$22.1M $27.57 234
2023 Q2 57.2M $1.72B +$49.4M $30.06 244
2023 Q1 55.3M $2B -$15.7M $36.23 254
2022 Q4 55.8M $1.99B +$8.21M $35.67 259
2022 Q3 55.6M $1.88B +$24.8M $33.85 235
2022 Q2 54.7M $1.58B +$42.2M $28.92 215
2022 Q1 53.5M $1.73B -$41.2M $32.32 223
2021 Q4 55.2M $1.61B +$18.5M $29.16 227
2021 Q3 54.4M $1.45B +$3.67M $26.67 218
2021 Q2 54.1M $1.67B +$29.2M $30.79 224
2021 Q1 53.3M $1.4B +$13.3M $26.18 217
2020 Q4 52.9M $1.33B +$29.1M $25.16 220
2020 Q3 51.5M $1.07B +$15.3M $20.84 205
2020 Q2 50.5M $1.2B +$48.6M $23.75 215
2020 Q1 48.5M $872M -$52.6M $17.99 201
2019 Q4 51.3M $1.22B +$7.79M $23.72 231
2019 Q3 50.6M $1.39B -$78.9M $27.48 238
2019 Q2 52.9M $1.75B -$145K $33.09 268
2019 Q1 53M $1.86B +$46.1M $35.04 282
2018 Q4 51.7M $1.72B -$19.9M $33.22 265
2018 Q3 51.7M $2.6B -$126M $50.35 284
2018 Q2 53.6M $3.21B +$163M $59.85 317
2018 Q1 51.3M $2.34B +$81.5M $45.80 309
2017 Q4 49.7M $1.98B -$48.8M $39.85 293
2017 Q3 50.8M $2.03B +$110M $40.00 273
2017 Q2 47.3M $2.04B +$105M $43.10 264
2017 Q1 46.1M $1.44B +$218M $31.30 246
2016 Q4 45.3M $1.14B -$18.6M $25.25 230
2016 Q3 46M $1.14B -$9.18M $24.73 218
2016 Q2 46.5M $948M +$64.7M $20.37 210
2016 Q1 44.8M $683M +$7.56M $15.25 211
2015 Q4 44.8M $602M -$43M $13.44 205
2015 Q3 46.8M $657M +$62.3M $14.03 180
2015 Q2 42.5M $722M +$80M $16.98 163
2015 Q1 40.5M $489M +$44.9M $12.09 118
2014 Q4 37.1M $308M +$10.4M $8.30 106
2014 Q3 35.6M $310M -$18.1M $8.69 93
2014 Q2 37.1M $405M +$42.4M $10.95 89
2014 Q1 33.4M $298M +$21.6M $8.94 81